Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Current Assets
All assets expected to be converted to cash or used up within one year.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 26.3% from a year ago
Total current assets stood at $107.72M at the end of Q1 FY2026, down 26.3% from a year earlier and down 7.5% from the prior quarter. Over 3 fiscal years it compounded at +52.5% a year.
Context
- Total current assets amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -26.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 116.4M USD
- Year-over-year change
- -23.8%
- 4-year CAGR
- +18.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 116.4M | -23.8% |
| FY2024 | 2024-12-31 | 152.77M | +58.1% |
| FY2023 | 2023-12-31 | 96.65M | +194.7% |
| FY2022 | 2022-12-31 | 32.79M | -44.1% |
| FY2021 | 2021-12-31 | 58.66M | — |
Total Current Assets vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total current assets of $107.72M is the 9th highest of the 11 companies compared; the peer median is $221.94M.
- Its year-over-year change of -26.3% is the 8th highest of 11, against a peer median of -15.1%.
- Total current assets amounts to 100.0% of total assets for SGMT, versus a peer median of 86.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $161.41B | +422369.0% | +17.5% | 75.1% | |
| Mar 2026 | $266.87M | -33.8% | +13.4% | 79.5% | |
| Mar 2026 | $263.2M | -39.3% | -22.2% | 98.5% | |
| Mar 2026 | $232.61M | +143.5% | +37.9% | 98.8% | |
ZURAZura Bio Limited | Mar 2026 | $227M | +32.2% | +298.4% | 99.3% |
| Mar 2026 | $216.88M | -22.2% | -15.7% | 88.4% | |
| Mar 2026 | $188.06M | -16.6% | -22.6% | 84.6% | |
| Mar 2026 | $146.98M | -40.1% | +17.6% | 67.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $107.72M | -26.3% | +52.5% | 100.0% |
| Mar 2026 | $63.6M | -13.7% | -24.0% | 57.5% | |
| Mar 2026 | $31.06M | +24.2% | +13.4% | 93.8% | |
| Peer median (excluding SGMT) | $221.94M | -15.1% | +13.4% | 86.5% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.